Efficacy analysis of domestic drug-carrying microspheres CalliSpheres for bronchial artery chemoembolization in the treatment of stage Ⅲ~Ⅳ non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2025.05.005

Abstract

Abstract:

Objective

To analyze the clinical efficacy of CalliSpheres^® drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) in the treatment of stage Ⅲ~Ⅳ non-small cell lung cancer (NSCLC).

Methods

A retrospective analysis was conducted on 23 stage Ⅲ~Ⅳ NSCLC patients treated with DEB-BACE (observation group) and 23 patients treated with conventional BACE (C-BACE, control group) at our hospital from May 2019 to October 2024. Clinical efficacy and quality of life were compared between the two groups before and after treatment.

Results

After BACE treatment, partial response (PR) was observed in 18 cases and stable disease (SD) in 23 cases. The objective response rate (ORR) in the observation group 56.52% was higher than that in the control group 21.74% (P=0.016). No grade 3 or higher adverse reactions occurred during BACE treatment, while 23 cases (50.00%) experienced grade 1-2 adverse reactions. The adverse reactions of 7 cases(30.43%) in the observation group was lower than 16 cases(69.57%) in the control group (P<0.05). In the observation group, significant improvements were observed in physical function (F_time=14.497), role function (F_time=6.696), cognitive function (F_time=4.839), and constipation symptoms (F_time=22.000) after treatment (P<0.05). Additionally, quality of life (F_group=10.863), dyspnea (F_group=19.101), loss of appetite (F_group=9.134), and diarrhea (F_group=22.000) showed greater improvement in the observation group compared to the control group (P<0.05), with hemoptysis symptoms effectively controlled. During a median follow-up of 6.22 months (0.47~20.80 months), 31 patients (67.39%) survived and 15 (32.61%) died, including 5 deaths (21.75%) in the observation group and 10 deaths (43.48%) in the control group. Kaplan-Meier curves indicated no statistically significant difference in median overall survival between the two groups (P=0.181).

Conclusion

CalliSpheres^® DEB-BACE demonstrates favorable safety and efficacy in treating stage Ⅲ~Ⅳ NSCLC, contributes to improved quality of life, and serves as a valuable alternative option for patients with stage Ⅲ~Ⅳ NSCLC.

Key words: Non-small cell lung cancer, Drug-eluting bronchial artery chemoembolization, CalliSpheres drug-loaded microspheres, Quality of life, Safety

Wentao Zheng, Jing Xiao, Bing Ouyang, Yi Wu, Kaiyou Liao, Chunlin Li. Efficacy analysis of domestic drug-carrying microspheres CalliSpheres for bronchial artery chemoembolization in the treatment of stage Ⅲ~Ⅳ non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(05): 691-696.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2025.05.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2025/V18/I05/691

Figures/Tables 3

References 30

1	张爱岐，李蕙颖，岱德羽. 1992-2021年中国肺癌疾病负担的年龄-时期-队列分析及预测[J]. 临床肺癌杂志，2025, 30(5): 649-655.
2	陈旭，牛凯，孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J/OL]. 中华肺部疾病杂志(电子版), 2024, 16(3): 341-348.
3	Jeon H, Wang S, Song J, et al. Update 2025: management of non-small-cell lung cancer[J]. Lung, 2025, 203(1): 53.
4	Patil NS, Nabet BY, Müller S, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer[J]. Cancer Cellm, 2022, 40(3): 289-300.
5	Filippi AR, Bar J, Chouaid C, et al. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage Ⅲ NSCLC: interim analysis of overall survival from PACIFIC-R[J]. ESMO Open, 2024, 9(6): 103464.
6	中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南患者版(2024版)[J]. 中华肿瘤杂志，2025, 47(1): 26-38.
7	国家卫生健康委办公厅. 原发性肺癌诊疗指南(2022年版)[J]. 协和医学杂志，2022, 13(4): 549-570.
8	Xu S, Bie ZX, Li YM, et al. Drug-eluting bead bronchial arterial chemoembolization with and without microwave ablation for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer: a comparative study[J]. Front Oncol, 2022, 12: 851830.
9	梁超，李浩，韩大千，等. 支气管动脉灌注化疗栓塞联合替雷利珠单抗治疗晚期非小细胞肺癌的有效性与安全性[J]. 介入放射学杂志，2025, 34(2): 148-153.
10	Klug M. Bronchial or pulmonary artery chemoembolization for unresectable and unablatable lung metastases[J]. Radiol Imaging Cancer, 2021, 3(6): e219023.
11	Xu S, Bie ZX, Li YM, et al. Maintenance treatment of immunotherapy after microwave ablation plus drug-eluting bead bronchial arterial chemoembolization for advanced non-small cell lung cancer: a retrospective single-center cohort study[J]. Quant Imaging Med Surg, 2024, 14(5): 3473-3488.
12	刘荣，宁厚法，崔新江. 支气管动脉化疗栓塞联合替雷利珠单抗治疗局部晚期非小细胞肺癌临床效果分析[J]. 介入放射学杂志，2025, 34(5): 477-481.
13	陈奉伟，刘现闯，鲍志宇，等. CalliSpheres载药微球经导管动脉化疗栓塞术治疗恶性肿瘤的应用进展[J]. 医学影像学杂志，2025, 35(1): 135-138.
14	Zhao YW, Liu S, Qin H, et al. Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study[J]. Front Oncol, 2023, 13: 1110917.
15	中国医师协会介入医师分会. 支气管动脉栓塞治疗咯血专家共识[J]. 中华内科杂志，2025, 64(3): 191-199.
16	Xu Y, Ma D, Qin Y, et al. Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC？[J]. Thorac Cancer, 2023, 14(17): 1635-1639.
17	白桦，王文慧，李瑞君，等. 培美曲塞和多西他赛对一线化疗失败的晚期非小细胞肺癌患者短期生存率、ALI及血清肿瘤标志物水平的影响[J]. 分子诊断与治疗杂志，2025, 17(2): 350-353，357.
18	Franken MD, de Hond A, Degeling K, et al. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model[J]. Health Qual Life Outcomes, 2020, 18(1): 240.
19	Zhang Q, Tang L, Zhou Y, et al. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management[J]. Front Immunol, 2021, 12: 663986.
20	Naidoo J, Antonia S, Wu YL, et al. Brief report: durvalumab after chemoradiotherapy in unresectable stage Ⅲ EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC[J]. J Thorac Oncol, 2023, 18(5): 657-663.
21	Guo Y, Li L, Zheng K, et al. Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression[J]. Front Immunol, 2024, 15: 1431150.
22	蔡忠，李婷，彭玲. 非小细胞肺癌患者射频消融治疗后T淋巴细胞亚群特点及其与肿瘤相关性死亡的关系[J]. 中国免疫学杂志，2025, 41(1): 93-99.
23	中国老年保健协会肺癌专业委员会，北京肿瘤学会肺癌专业委员会. 老年晚期肺癌内科治疗中国专家共识(2022版)[J]. 中国肺癌杂志，2022, 25(6): 363-384.
24	王国安，吴宏成. 经支气管动脉介入治疗在呼吸疾病中的应用[J]. 现代实用医学，2021, 33(1): 6-8.
25	Nezami N, Georgiades C, Hong KK, et al. Bronchial artery chemoembolization with radiopaque doxorubicin eluding beads in patients with malignant hemoptysis from metastatic lung cancer[J]. Technol Cancer Res Treat, 2022, 21: 15330338221131167.
26	胡胤，李甜甜，贾薇，等. 支气管动脉化疗栓塞术在肺癌咯血中的应用进展[J]. 临床医学进展，2025, 15(2): 428-435.
27	常晓菲，关利君. 载药微球支气管动脉化疗栓塞术治疗肺癌的研究进展[J]. 实用肿瘤杂志，2025, 40(2): 120-127.
28	张辉，张庆桥，袁磊，等. CalliSpheres D-TACE与c-TACE治疗原发性肝癌对肝纤维化和肝功能的影响[J]. 介入放射学杂志，2024, 33(3): 259-263.
29	程瑞文，郝若冰，李平，等. CalliSpheres药物洗脱微球和空白微球经动脉化疗栓塞术治疗Ⅲ~Ⅳ期非小细胞肺癌的比较[J]. 实用医学杂志，2024, 40(1): 32-37.
30	江强，黄燕群，王红珍，等. CalliSpheres载药微球在Ⅲ~Ⅳ期非小细胞肺癌合并咯血中的应用效果[J]. 中国医学创新，2022, 19(19): 9-12.

不良反应	观察组(n＝23)	对照组(n＝23)	Z/t/χ²	P值
胃肠道反应	3(13.04)	10(43.48)	3.860	0.049
骨髓抑制	4(17.39)	8(34.78)	1.015	0.314
神经毒性	4(17.39)	8(34.78)	1.015	0.314
肾毒性	3(13.04)	8(34.78)	1.912	0.167
肝毒性	3(13.04)	6(26.08)	0.552	0.457
胸痛	2(8.70)	9(39.13)	4.301	0.038
共计	7(30.43)	16(69.57)	7.043	0.008

不良反应	观察组(n＝23)	对照组(n＝23)	Z/t/χ²	P值
胃肠道反应	3(13.04)	10(43.48)	3.860	0.049
骨髓抑制	4(17.39)	8(34.78)	1.015	0.314
神经毒性	4(17.39)	8(34.78)	1.015	0.314
肾毒性	3(13.04)	8(34.78)	1.912	0.167
肝毒性	3(13.04)	6(26.08)	0.552	0.457
胸痛	2(8.70)	9(39.13)	4.301	0.038
共计	7(30.43)	16(69.57)	7.043	0.008

变　量	观察组(n＝23)	对照组(n＝23)
躯体功能
治疗前	33.00(17.00，67.00)	60.00(20.00，73.00)
治疗后	80.00(60.00，93.00)	53.00(47.00，73.00)
角色功能
治疗前	50.00(17.00，50.00)	33.00(0.00，83.00)
治疗后	83.00(67.00，100.00)	33.00(17.00，83.00)
情绪功能
治疗前	58.00(25.00，75.00)	50.00(33.00，75.00)
治疗后	83.00(50.00，100.00)	42.00(25.00，83.00)
认知功能
治疗前	50.00(17.00，67.00)	67.00(17.00，83.00)
治疗后	83.00(50.00，100.00)	50.00(17.00，83.00)
社交功能
治疗前	50.00(17.00，67.00)	67.00(17.00，83.00)
治疗后	50.00(17.00，63.00)	50.00(17.00，83.00)
生活质量
治疗前	33.00(25.00，92.00)	33.00(17.00，83.00)
治疗后	67.00(50.00，100.00)	42.00(17.00，50.00)
疲劳
治疗前	44.00(11.00，78.00)	56.00(33.00，78.00)
治疗后	56.00(33.00，78.00)	67.00(44.00，100.00)
恶心呕吐
治疗前	50.00(17.00，50.00)	33.00(17.00，67.00)
治疗后	33.00(17.00，50.00)	100.00(67.00，100.00)
疼痛
治疗前	33.00(0.00，100.00)	50.00(0.00，100.00)
治疗后	50.00(0.00，83.00)	83.00(50.00，100.00)
呼吸困难
治疗前	33.00(0.00，100.00)	100.00(0.00，100.00)
治疗后	3.00(0.00，67.00)	100.00(33.00，100.00)
失眠
治疗前	67.00(0.00，100.00)	67.00(33.00，100.00)
治疗后	33.00(0.00，100.00)	100.00(33.00，100.00)
食欲不振
治疗前	33.00(0.00，100.00)	33.00(0.00，100.00)
治疗后	0.00(0.00，33.00)	100.00(33.00，100.00)
便秘
治疗前	100.00(33.00，100.00)	100.00(0.00，100.00)
治疗后	33.00(0.00，100.00)	100.00(33.00，100.00)
腹泻
治疗前	33.00(0.00，100.00)	33.00(0.00，100.00)
治疗后	0.00(0.00，100.00)	100.00(100.00，100.00)
经济困难
治疗前	33.00(0.00，100.00)	33.00(0.00，100.00)
治疗后	33.00(0.00，100.00)	33.00(0.00，100.00)

变　量	观察组(n＝23)	对照组(n＝23)
躯体功能
治疗前	33.00(17.00，67.00)	60.00(20.00，73.00)
治疗后	80.00(60.00，93.00)	53.00(47.00，73.00)
角色功能
治疗前	50.00(17.00，50.00)	33.00(0.00，83.00)
治疗后	83.00(67.00，100.00)	33.00(17.00，83.00)
情绪功能
治疗前	58.00(25.00，75.00)	50.00(33.00，75.00)
治疗后	83.00(50.00，100.00)	42.00(25.00，83.00)
认知功能
治疗前	50.00(17.00，67.00)	67.00(17.00，83.00)
治疗后	83.00(50.00，100.00)	50.00(17.00，83.00)
社交功能
治疗前	50.00(17.00，67.00)	67.00(17.00，83.00)
治疗后	50.00(17.00，63.00)	50.00(17.00，83.00)
生活质量
治疗前	33.00(25.00，92.00)	33.00(17.00，83.00)
治疗后	67.00(50.00，100.00)	42.00(17.00，50.00)
疲劳
治疗前	44.00(11.00，78.00)	56.00(33.00，78.00)
治疗后	56.00(33.00，78.00)	67.00(44.00，100.00)
恶心呕吐
治疗前	50.00(17.00，50.00)	33.00(17.00，67.00)
治疗后	33.00(17.00，50.00)	100.00(67.00，100.00)
疼痛
治疗前	33.00(0.00，100.00)	50.00(0.00，100.00)
治疗后	50.00(0.00，83.00)	83.00(50.00，100.00)
呼吸困难
治疗前	33.00(0.00，100.00)	100.00(0.00，100.00)
治疗后	3.00(0.00，67.00)	100.00(33.00，100.00)
失眠
治疗前	67.00(0.00，100.00)	67.00(33.00，100.00)
治疗后	33.00(0.00，100.00)	100.00(33.00，100.00)
食欲不振
治疗前	33.00(0.00，100.00)	33.00(0.00，100.00)
治疗后	0.00(0.00，33.00)	100.00(33.00，100.00)
便秘
治疗前	100.00(33.00，100.00)	100.00(0.00，100.00)
治疗后	33.00(0.00，100.00)	100.00(33.00，100.00)
腹泻
治疗前	33.00(0.00，100.00)	33.00(0.00，100.00)
治疗后	0.00(0.00，100.00)	100.00(100.00，100.00)
经济困难
治疗前	33.00(0.00，100.00)	33.00(0.00，100.00)
治疗后	33.00(0.00，100.00)	33.00(0.00，100.00)

[1]	Lulu Dai, Jinhua Pan, Yuxia Kong, Tian'an Jiang. Radiofrequency ablation versus surgical treatment for papillary thyroid microcarcinoma: a multidimensional comparative study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2025, 22(05): 444-450.
[2]	Yaru Zhang, Chuan Pang, Yu Pang, Fangying Fan, Ping Liang, Jie Yu. Effect of ablation on quality of life and depressive status in patients with T1N0M0 papillary thyroid cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2025, 22(04): 328-336.
[3]	Yaping Deng, Yinying Qiu, Qiuyue Shao, Zhimin Yu, Qin Li, Xinyan Yu. Application of healthcare failure mode and effect analysis in safety management of clinical trial drug infusion [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2025, 18(04): 282-289.
[4]	Long Chen, Xiaoxin Duan, Sizhuo Wang, Shengli Dong. Current status of immunotherapy for gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 177-182.
[5]	Binyan Liu, Yubing Zhu, Huimin Li, Mengdi Hao, Xiaoli Liu, Dajin Yuan, Wenbin Huang, Wenjie Li, Jia Zeng, Lei Ding. Preoperative CT angiography combined with three-dimensional reconstruction in colorectal cancer surgery： A Meta-analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 209-216.
[6]	Zhengyuan Yan, Heng Zhang, Nengqi Cao, Xingchao Fang, Damin Chen. Clinical observation on the efficacy and safety of single-port plus one laparoscopic radical resection for colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 615-618.
[7]	Linpu Xin, Min Yang, Junfeng Du. The influence of the evidence-based program of “five fixations and four observations” on the quality of life and application effect of patients with rectal cancer stoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(04): 409-412.
[8]	Yawei Zhang, Qi Liu, Jianwu Jiang, Rui Deng, Yang Fu. Analysis of 6 cases of one-stage repair of stoma reversal combined with giant incisional hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2025, 19(03): 276-280.
[9]	Xiaoli Liu, Qian Luo, Yuting Chong, Yun Xiang, Qunbao Ma, Rehemula Moyasier·, Yurong Huang. Efficacy of anti-angiogenic drugs combined with PD-1 blockade in NSCLC treatment and its efficacy on T lymphocytes [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(04): 510-515.
[10]	Yanling Jiang, Jinzhuo Ren, Junjie Chen, Xiuli Tian, Yixiang Shen, Hua Zhang. Significance of plasma cytokine profile in predicting clinical benefits and immune related adverse events in patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(04): 558-563.
[11]	Xuefei Liu, Dong Zhao, Tingting Li, Jianong Li, Yanan Ge, Bo Li. Clinical significance of RB1 gene status predicting the response to immune checkpoint inhibitor combined with chemotherapy in patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(04): 580-585.
[12]	Wenjie Li, Pei Shi, Rui Zhao, Jiao Mu, Dongdong Wei, xing Gu. Safety and efficacy analysis of hyperpulsed Nd︰YAG laser ablation for central airway stenosis [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(04): 586-591.
[13]	Junxia Wu, Gang Huo, Jiaojiao Li, Huihui Yang, Ming Ma, Wangfeng Zhang. Clinical significance of circulating cytokine profiles in predicting radioactive pulmonary fibrosis in patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(04): 603-608.
[14]	Yuzhen Liu, Zheng Wang, Shujun Li, Rui Zhao, Qinghua Xu. Rehabilitation effect of dietary management combined with exercise therapy on patients with functional dyspepsia [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(04): 412-416.
[15]	Yan Shao, Caijuan Wu, Youjun Mao, Dongmei Li, Yunzhou Wang, Jiao Guo, Kang Zhu. Application of comprehensive nursing based on the "3P model" in interventional treatment of patients with acute aortic dissection [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2025, 11(04): 229-232.

Please choose a citation manager

Content to export